The eradication of cervical cancer is on the horizon, stirring further competition between biopharma companies developing novel cancer vaccines.
There has been progress in the development of therapeutic vaccines, notably in oncology, and advances in the production of cervical cancer treatments.
Cervical cancer is a serious illness that affects women of all ages but is most frequently diagnosed between the ages...
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
